Matches in SemOpenAlex for { <https://semopenalex.org/work/W4205358180> ?p ?o ?g. }
- W4205358180 endingPage "106" @default.
- W4205358180 startingPage "106" @default.
- W4205358180 abstract "Diabetes mellitus (DM), a complicated metabolic disorder, is due to insensitivity to insulin function or reduction in insulin secretion, which results in postprandial hyperglycemia. α-Glucosidase inhibitors (AGIs) and α-amylase inhibitors (AAIs) block the function of digestive enzymes, which delays the carbohydrate hydrolysis process and ultimately helps to control the postprandial hyperglycemia. Diversified 2-(3-(3-methoxybenzoyl)-4-hydroxy-1,1-dioxido-2H-benzo[e][1,2]thiazin-2-yl)-N-arylacetamides were synthesized and evaluated for their in vitro inhibitory potential against α-glucosidase and α-amylase enzymes. The compounds with chloro, bromo and methyl substituents demonstrated good inhibition of α-glucosidase enzymes having IC50 values in the range of 25.88-46.25 μM, which are less than the standard drug, acarbose (IC50 = 58.8 μM). Similarly, some derivatives having chloro, bromo and nitro substituents were observed potent inhibitors of α-amylase enzyme, with IC50 values of 7.52 to 15.06 μM, lower than acarbose (IC50 = 17.0 μM). In addition, the most potent compound, N-(4-bromophenyl)-2-(4-hydroxy-3-(3-methoxybenzoyl)-1,1-dioxido-2H-benzo[e][1,2]thiazin-2-yl)acetamide (12i), was found to be a non-competitive and competitive inhibitor of α-glucosidase and α-amylase enzymes, respectively, during kinetic studies. The molecular docking studies provided the binding modes of active compounds and the molecular dynamics simulation studies of compound 12i in complex with α-amylase also showed that the compound is binding in a fashion similar to that predicted by molecular docking studies." @default.
- W4205358180 created "2022-01-25" @default.
- W4205358180 creator A5007598907 @default.
- W4205358180 creator A5015817802 @default.
- W4205358180 creator A5059584871 @default.
- W4205358180 creator A5080661827 @default.
- W4205358180 creator A5082265904 @default.
- W4205358180 creator A5090444668 @default.
- W4205358180 date "2022-01-17" @default.
- W4205358180 modified "2023-09-30" @default.
- W4205358180 title "Identification of Cyclic Sulfonamides with an N-Arylacetamide Group as α-Glucosidase and α-Amylase Inhibitors: Biological Evaluation and Molecular Modeling" @default.
- W4205358180 cites W1138321198 @default.
- W4205358180 cites W1911192986 @default.
- W4205358180 cites W1950734766 @default.
- W4205358180 cites W1963928184 @default.
- W4205358180 cites W1964702204 @default.
- W4205358180 cites W1966336396 @default.
- W4205358180 cites W1972153696 @default.
- W4205358180 cites W1973393804 @default.
- W4205358180 cites W1976499671 @default.
- W4205358180 cites W1983273863 @default.
- W4205358180 cites W1994977169 @default.
- W4205358180 cites W2002750392 @default.
- W4205358180 cites W2003919273 @default.
- W4205358180 cites W2007641214 @default.
- W4205358180 cites W2011053226 @default.
- W4205358180 cites W2017096916 @default.
- W4205358180 cites W2027743229 @default.
- W4205358180 cites W2033183607 @default.
- W4205358180 cites W2033882981 @default.
- W4205358180 cites W2038644716 @default.
- W4205358180 cites W2052330771 @default.
- W4205358180 cites W2067174909 @default.
- W4205358180 cites W2069123478 @default.
- W4205358180 cites W2077928936 @default.
- W4205358180 cites W2084205148 @default.
- W4205358180 cites W2087314182 @default.
- W4205358180 cites W2090018187 @default.
- W4205358180 cites W2091548691 @default.
- W4205358180 cites W2102694004 @default.
- W4205358180 cites W2106140689 @default.
- W4205358180 cites W2118233996 @default.
- W4205358180 cites W2120704605 @default.
- W4205358180 cites W2134719480 @default.
- W4205358180 cites W2152630148 @default.
- W4205358180 cites W2155905771 @default.
- W4205358180 cites W2156835501 @default.
- W4205358180 cites W2167901867 @default.
- W4205358180 cites W2168261002 @default.
- W4205358180 cites W2172993971 @default.
- W4205358180 cites W2174169848 @default.
- W4205358180 cites W2174784258 @default.
- W4205358180 cites W2258293349 @default.
- W4205358180 cites W2282002527 @default.
- W4205358180 cites W2317025935 @default.
- W4205358180 cites W2344199479 @default.
- W4205358180 cites W2460998067 @default.
- W4205358180 cites W2461958429 @default.
- W4205358180 cites W2473850827 @default.
- W4205358180 cites W2479484746 @default.
- W4205358180 cites W2513881796 @default.
- W4205358180 cites W2550842290 @default.
- W4205358180 cites W2594266236 @default.
- W4205358180 cites W2717516683 @default.
- W4205358180 cites W2762973783 @default.
- W4205358180 cites W2765198217 @default.
- W4205358180 cites W2797477032 @default.
- W4205358180 cites W2803196848 @default.
- W4205358180 cites W2805853181 @default.
- W4205358180 cites W2806121054 @default.
- W4205358180 cites W2810533222 @default.
- W4205358180 cites W2891219090 @default.
- W4205358180 cites W2894756780 @default.
- W4205358180 cites W2967870546 @default.
- W4205358180 cites W2973828898 @default.
- W4205358180 cites W2981783548 @default.
- W4205358180 cites W2990231378 @default.
- W4205358180 cites W2995395833 @default.
- W4205358180 cites W3043166064 @default.
- W4205358180 cites W3046699175 @default.
- W4205358180 cites W3092355749 @default.
- W4205358180 cites W3096090415 @default.
- W4205358180 cites W3097499475 @default.
- W4205358180 cites W3108345793 @default.
- W4205358180 cites W3115203426 @default.
- W4205358180 cites W3117659384 @default.
- W4205358180 cites W3123640346 @default.
- W4205358180 cites W3127242553 @default.
- W4205358180 cites W3161535006 @default.
- W4205358180 cites W3166474818 @default.
- W4205358180 cites W3196655661 @default.
- W4205358180 cites W3196765255 @default.
- W4205358180 cites W4214826712 @default.
- W4205358180 cites W896551578 @default.
- W4205358180 doi "https://doi.org/10.3390/ph15010106" @default.
- W4205358180 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35056163" @default.
- W4205358180 hasPublicationYear "2022" @default.
- W4205358180 type Work @default.